Trials / Recruiting
RecruitingNCT07442006
Glycemic Variability of Combination Therapies in T2DM
A Multicenter Study to Evaluate Efficacy and Safety
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 178 (estimated)
- Sponsor
- JW Pharmaceutical · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
Glycemic Variability of Combination Therapies in T2DM
Detailed description
A multicenter study to evaluate efficacy and safety
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Empagliflozin/Metformin | 5/500 mg, 5/1000 mg (based on prior Metformin dose), for 12 weeks (PO, BID) |
| DRUG | Anagliptin | 100 mg, for 12 weeks (PO, BID) |
| DRUG | Metformin | 500 mg, 1000 mg (based on prior Metformin dose), for 12 weeks (PO, BID) |
| DRUG | Empagliflozin/Linagliptin | 10/5 mg, for 12 weeks (PO, QD) |
Timeline
- Start date
- 2025-10-29
- Primary completion
- 2027-03-31
- Completion
- 2027-03-31
- First posted
- 2026-03-02
- Last updated
- 2026-03-02
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT07442006. Inclusion in this directory is not an endorsement.